

List of Publications, E.W. Radue

Articles

1. Caduff F, Staub JJ, Nordmann A, Radue EW, Landolt H. [The diagnosis of Cushing's syndrome. Results of diagnostic assessment of 20 patients with Cushing's syndrome of variable etiology (1979-1989)]. *Schweiz Med Wschr* 1991;121:10-20
2. Kappos L, Gold R, Hofmann E, Grimminger V, Keil W, Kuenstler E, Radue. Magnetic resonance imaging: Contribution to early diagnosis and monitoring disease activity in therapeutic trials. Amsterdam, New York, Oxford, Excerpta Medica, In Wiethölder H, Dichgans J, Mertin J (eds): *Current concepts in multiple sclerosis*;1991:23-28
3. Kappos L, Gold R, Staedt D, Heun R, Keil W, Radue EW. MS: Definite diagnosis at first presentation? The role of Gd-enhanced MRI. *Neurology*, 1991;41:191
4. Kappos L, Radue EW. Magnetische Resonanztomographie bei Multipler Sklerose. Eine Bestandsaufnahme. *Klin Neuroradiologie* 1991;1:110-126
5. Friedli WG, Gratzl O, Radue EW. Lipoma of the cauda equina selectively involving lower sacral roots. Case report. *Eur Neurol* 1991;32:267-9
6. Kaufmann MA, Buchmann B, Scheidegger D, Gratzl O, Radue EW. Severe head injury: should expected outcome influence resuscitation and first-day decisions? *Resuscitation* 1992;23:199-206
7. Reymond MA, Marbet G, Radue EW, Gratzl O. Aspirin as a risk factor for hemorrhage in patients with head injuries. *Neurosurg Rev* 1992;15:21-5
8. Kappos L, Radue EW, Bernasconi L, Brunnschweiler H, Hartung HP, Haas J, Gehlen W, Hartard C, Lagreze HL, Ruettinger H. Treatment of multiple sclerosis with 15 +/- deoxyspergualin. Design of a controlled study with close MRI-monitoring. *Schweiz Arch Neurol Psychiatr* 1993;144:198-201
9. Schnabel K, Stock KW, Radue EW. [Radiologic assessment of suspected orbital fracture]. *Klin Monatsbl Augenh* 1993;202:455-7
10. Stock KW, Mueller T, Radue EW, Steinbrich W. [Intracranial lymphoma. Radiologic findings in 40 patients]. *Rofo-Fortschr Rontg* 1993;158:565-9
11. Stock KW, Radue EW, Steinbrich W. [Visualization of the normal basilar artery and its branches using magnetic resonance angiography (MRA)]. *Aktuelle Radiol* 1993;3:161-6
12. Tsakiris DA, Stock KW, Muerner J, Radue EW, Maeder G, Marbet GA. [Local therapeutic fibrinolysis in ischemic cerebrovascular insults: initial findings in 6 patients]. *Schweiz Med Wschr* 1993;123:1784-9
13. Radue EW, Scollo-Lavizzari G. Computed tomography and magnetic resonance imaging in epileptic seizures. *Eur Neurol* 1994;34 Suppl 1: 55-7
14. Stahl HD, Ettl TH, Plohmann A, Radue EW, Mueller-Brand J, Steiger U, Tyndall A. Central nervous system lupus: concomitant occurrence of myelopathy and cognitive dysfunction. *Clin Rheumatol* 1994;13:273-9
15. Hagberg G, Burlina AP, Mader I, Roser W, Radue EW, Seelig J. In vivo proton MR spectroscopy of human gliomas: definition of metabolic coordinates for multi-dimensional classification. *Magnet Reson Med* 1995;34:242-52
16. Kaim A, Mader I, Kirsch E, Radue EW, Steinbrich W. [Perimesencephalic subarachnoid hemorrhage: clinical and computer tomography aspects]. *Rofo-Fortschr Rontg* 1995;162:274-81
17. Roelcke U, Kappos L, Lechner-Scott J, Brunnschweiler H, Ammann W, Plohmann A, Dellas S, Radue EW, Steck AJ, Leenders KL. Reduced glucose metabolism in the frontal cortex and caudate nucleus in multiple sclerosis patients with fatigue. *J Cerebr Blood F Met* 1995;15:820
18. Roelcke U, Radue EW, von Ammon K, Hausmann O, Maguire RP, Leenders KL. Alteration of blood-brain barrier in human brain tumors: comparison of [18F]fluorodeoxyglucose, [11C]methionine and rubidium-82 using PET. *J Neurol Sci* 1995;132:20-7

19. Roser W, Hagberg G, Mader I, Brunnschweiler H, Radue EW, Seelig J, Kappos L. Proton MRS of gadolinium-enhancing MS plaques and metabolic changes in normal-appearing white matter. *Magnet Reson Med* 1995;33:811-7
20. Roser W, Hagberg G, Mader I, Radue EW, Brunnschweiler H, Kappos L, Seelig J. ¹H MR spectroscopy in multiple sclerosis. *John Libbey Eurotext, Paris* 1995:pp421-427
21. Stock KW, Mader I, Schneider U, Radue EW, Steinbrich W. MR imaging of lumbosacral conjoint nerve roots. *Neuro-Orthopedics* 1995:pp95-100
22. Stock KW, Radue EW, Jacob AL, Bao XS, Steinbrich W. Intracranial arteries: prospective blinded comparative study of MR angiography and DSA in 50 patients. *Radiology* 1995;195:451-6
23. Kaim A, Proske M, Kirsch E, von Weymarn A, Radue EW, Steinbrich W. Value of repeat-angiography in cases of unexplained subarachnoid hemorrhage (SAH). *Acta Neurol Scan* 1996;93:366-73
24. Kappos L, Radue EW, Dellas S, Hartard C, Hartung HP, Haller P. 15 \pm deoxyspergualine in the treatment of active MS: final analysis of the European multicenter study. *Neurology* 1996;46:A410-411
25. Kirsch E, Hausmann O, Kaim A, Gratzl O, Steinbrich W, Radue EW. Magnetic resonance imaging of vertebrobasilar ectasia in trigeminal neuralgia. *Acta Neurochir* 1996;138:1295-8; discussion 1299
26. Mader I, Roser W, Hagberg G, Schneider M, Sauter R, Seelig J, Radue EW, Steinbrich W. Proton chemical shift imaging, metabolic maps, and single voxel spectroscopy of glial brain tumors. *Magn Reson Mater Phy* 1996;4:139-50
27. Mader I, Stock KW, Radue EW, Steinbrich W. Langerhans cell histiocytosis in monozygote twins: case reports. *Neuroradiology* 1996;38:163-5
28. Mader I, Stock KW, Radue EW, Steinbrich W. Langerhans cell histiocytosis in monozygote twins: Case reports. *Neuroradiology* 1996;38:163-163
29. Roelcke U, Leenders KL, von Ammon K, Radue EW, Vontobel P, Guenther I, Psylla M. Brain tumor iron uptake measured with positron emission tomography and ⁵²Fe-citrate. *J Neuro-Oncol* 1996;29:157-65
30. Roelcke U, Radue E, Ametamey S, Pellikka R, Steinbrich W, Leenders KL. Association of rubidium and C-methionine uptake in brain tumors measured by positron emission tomography. *J Neuro-Oncol* 1996;27:163-71
31. Stock KW, Wetzel S, Kirsch E, Bongartz G, Steinbrich W, Radue EW. Anatomic evaluation of the circle of Willis: MR angiography versus intraarterial digital subtraction angiography. *Am J Neuroradiol* 1996;17:1495-9
32. Andresen B, Spycher M, Freitag P, Lechner-Scott J, Huber S, Leppert D, Radue EW, Kappos L. Recombinant interferon β -1b (rIFN β 1b) in the treatment of multiple sclerosis MRI follow-up. *Mult Scler* 1997;3:339
33. Barkhof F, Filippi M, van Waesberghe JH, Molyneux P, Rovaris M, Lycklama a Nijeholt G, Tubridy N, Miller DH, Yousry TA, Radue EW, Ader HJ. Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. *Neurology* 1997;49:1682-8
34. Boos M, Scheffler K, Ott HW, Radue EW, Bongartz G. [Conventional magnetic resonance angiography and contrast enhanced magnetic resonance angiography of extracranial blood vessel segments]. *Radiologe* 1997;37:515-28
35. Haselhorst R, Moeri D, Bilcen D, Scheffler K, Seelig J, Radue EW, Kappos L. Bolus tracking measurements of multiple sclerosis plaques. *Mult Scler* 1997;3:268
36. Jakubowski E, Kirsch E, Mindermann T, Ettlin D, Gratzl O, Radue EW. Intradiploic epidermoid cyst of the frontal bone presenting with tension pneumocephalus. *Acta Neurochir* 1997;139:86-7
37. Kaim A, Kirsch E, Tolnay M, Steinbrich W, Radue EW. Foramen of Monro mass: MRI appearances permit diagnosis of cavernous haemangioma. *Neuroradiology* 1997;39:265-9
38. Lyrer PA, Engelter S, Radue EW, Steck AJ. Cerebral infarcts related to isolated middle cerebral artery stenosis. *Stroke* 1997;28:1022-7

39. Moeri D, Radue EW, Freitag P, Kappos L. Diagnostik und Therapiekontrolle der Multiplen Sklerose: Die Rolle der Magnetresonanztomographie. *Neuroradiologica Helvetica* 1997;8:61-68
40. Otte A, Ostwald E, Rem JA, Goetze M, Radue EW, Mueller-Brand J. [Effect of thrombus endarterectomy (TEA) on the regional cerebral bloodflow (rCBF) in patients with unilateral internal carotid artery stenosis]. *Nuklearmed-Nucl Med* 1997;36:23-8
41. Radue EW, Kappos L. Bedeutung der Magnetresonanztomografie fuer die Diagnose und Therapiekontrolle der MS. 1997, Blackwell, Berlin
42. Roelcke U, Kappos L, Lechner-Scott J, Brunnschweiler H, Huber S, Ammann W, Plohmann A, Dellas S, Maguire RP, Missimer J, Radue EW, Steck A, Leenders KL. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a ¹⁸F-fluorodeoxyglucose positron emission tomography study. *Neurology* 1997;48:1566-71
43. Roser W, Hagberg G, Mader I, Dellas S, Seelig J, Radue EW, Steinbrich W. Assignment of glial brain tumors in humans by in vivo ¹H-magnetic resonance spectroscopy and multidimensional metabolic classification. *Magn Reson Mater Phy* 1997;5:179-83
44. Roser W, Steinbrich W, Radue EW. [Results and consequences of frequent quality control of quantitative clinical ¹H-MR-spectroscopy]. *Rofo-Fortschr Rontg* 1997;166:554-7
45. van Waesberghe JH, Castelijns JA, Roser W, Silver N, Yousry T, Lycklama a Nijeholt GJ, Ader HJ, Uitdehaag BM, Radue EW, Polman CH, Kappos L, Miller DH, Barkhof F. Single-dose gadolinium with magnetization transfer versus triple-dose gadolinium in the MR detection of multiple sclerosis lesions. *Am J Neuroradio* 1997;18:1279-85
46. Kappos L, Freitag P, Roelcke U, Radue EW. The role of functional MRI in multiple sclerosis first results and future developments. *Cephalalgia* 1998;6:13
47. Kappos L, Leppert D, Radue EW. Treatment: relapsing phase of multiple sclerosis. *Eur J Neurol* 1998;(Suppl 2),5:pp23-24
48. Kirsch E, Kaim A, Engelter S, Lyrer P, Stock KW, Bongartz G, Radue EW. MR angiography in internal carotid artery dissection: improvement of diagnosis by selective demonstration of the intramural haematoma. *Neuroradiology* 1998;40:704-9
49. Lienert C, Andresen B, Spycher M, Freitag P, Schoett D, Leppert D, Radue EW, Ambuehl Braun B, Kappos L. 2 year experience with rIFN beta-1b in Switzerland. *Mult Scler* 1998;4:375
50. Otte A, Roelcke U, von Ammon K, Hausmann O, Maguire RP, Missimer J, Mueller-Brand J, Radue EW, Leenders KL. Crossed cerebellar diaschisis and brain tumor biochemistry studied with positron emission tomography, [¹⁸F]fluorodeoxyglucose and [¹¹C]methionine. *J Neurol Sci* 1998;156:73-7
51. Radue EW, Kappos L. Bedeutung der Magnetresonanztomographie (MRT) fuer die Diagnostik und Therapiekontrolle bei der Multiplen Sklerose. *Radiologie aktuell* 1998:pp3-7
52. Roelcke U, Blasberg RG, von Ammon K, Hofer S, Vontobel P, Maguire RP, Radue EW, Herrmann R, Leenders KL. Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas. *J Nucl Med* 1998;39:879-84
53. Roelcke U, Radue EW, Hausmann O, Vontobel P, Maguire RP, Leenders KL. Tracer transport and metabolism in a patient with juvenile pilocytic astrocytoma. A PET study. *J Neuro-Oncol* 1998;36:279-83
54. Andresen B, Freitag P, Lienert C, Hoshi C, Fasciati M, Radue EW, Kappos L. Importance of qualitative T2 Lesion Evaluation in the Treatment of Relapsing-remitting Multiple Sclerosis with rIFN beta-1b. *Mult Scler* 1999:pp101
55. Bruehlmeier M, Roelcke U, Amsler B, Schubert KH, Hausmann O, von Ammon K, Radue EW, Gratzl O, Landmann C, Leenders KL. Effect of radiotherapy on brain glucose metabolism in patients operated on for low grade astrocytoma. *J Neurol Neurosurg Ps* 1999;66:648-53
56. Gass A, Radue EW, Filippi M, Kappos L. [MRI follow-up in multiple sclerosis. A guideline for quality assurance]. *Rofo-Fortschr Rontg* 1999;170:581-6
57. Gass A, Radue EW, Filippi M, Kappos L. Kernspintomographische Diagnostik und Verlaufsuntersuchungen bei Multipler Sklerose - Ein Leitfaden fuer die Qualitätssicherung. *Rofo-Fortschr Rontg* 1999;170:581-586

58. Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, Barkhof F, Miller D, Guttmann CR, Weiner HL, Gasperini C, Filippi M. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. *Gadolinium MRI Meta-analysis Group. Lancet* 1999;353:964-9
59. Lyrer P, Bont A, Marugg A, Operschall C, Radue EW. [Area reduction in carotid stenosis of the internal carotid artery]. *Ultraschall Med* 1999;20:137-43
60. Roelcke U, von Ammon K, Hausmann O, Kaech DL, Vanloffeld W, Landolt H, Rem JA, Gratzl O, Radue EW, Leenders KL. Operated low grade astrocytomas: a long term PET study on the effect of radiotherapy. *J Neurol Neurosurg Ps* 1999;66:644-7
61. Roser W, Bubl R, Buergin D, Seelig J, Radue EW, Rost B. Metabolic changes in the brain of patients with anorexia and bulimia nervosa as detected by proton magnetic resonance spectroscopy. *Int J Eat Disorder* 1999;26:119-36
62. Roser W, Dimitrovic I, Freitag P, Radue EW, Kappos L. H-MR spectroscopy of normal appearing grey matter of multiple-sclerosis patients. A longitudinal study. *Mult Scler* 1999;5:p89
63. Rost B, Roser W, Bubl R, Radue EW, Buergin D. MRS of the brain in patients with anorexia or bulimia nervosa. *Hosp Med* 1999;60:474-6
64. Welti D, Freitag P, Kappos L, Gerig G, Radue EW, Szekely G. A new method using spatio-temporal information to improve segmentation and characterization of lesions in MRI data. *Mult Scler* 1999;5:S57
65. Wetzel S, Boos M, Bongartz G, Radue EW. Selection of patients for carotid thromboendarterectomy: the role of magnetic resonance angiography. *J Comput Assist Tomo* 1999;23:pp91-4
66. Wetzel SG, Kirsch E, Stock KW, Kolbe M, Kaim A, Radue EW. Cerebral veins: comparative study of CT venography with intraarterial digital subtraction angiography. *Am J Neuroradiol* 1999;20:249-55
67. Bilecen D, Seifritz E, Radue EW, Schmid N, Wetzel S, Probst R, Scheffler K. Cortical reorganization after acute unilateral hearing loss traced by fMRI. *Neurology* 2000;54:765-7
68. Freitag P, Kappos L, Radue EW. Stellenwert der Magnetresonanztomographie bei Diagnose und Krankheitsmonitoring der Multiplen Sklerose. *Schw Arch fuer Neurol und Psych* 2000;151/2:47-56
69. Haselhorst R, Kappos L, Bilecen D, Scheffler K, Moeri D, Radue EW, Seelig J. Dynamic susceptibility contrast MR imaging of plaque development in multiple sclerosis: application of an extended blood-brain barrier leakage correction. *J Magn Reson Imaging* 2000;11:495-505
70. Mader I, Roser W, Kappos L, Hagberg G, Seelig J, Radue EW, Steinbrich W. Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. *Am J Neuroradiol* 2000;21:1220-7
71. Penner IK, Rausch M, Freitag P, Kappos L, Radue EW. Reproducibility of fMRI findings in the assessment of attentional tasks depends on task complexity. *Rev Neurol-France* 2000;156:104
72. Radue EW, Freitag P, Kappos L, Clanet M, Kooijmans M, for the-rIFN-beta-1a-dose-comparison-trial-study-group. MRI baseline data of a multicenter double-blind, dose-comparison trial of 30 vs 60 mcg rIFN -1a (Avonex) in patients with relapsing remitting multiple sclerosis. *Rev Neurol-France* 2000;156:135
73. Radue EW, Kappos L. Therapiekontrolle mittels Magnetresonanztomografie: Befunde der europaeischen Multizenterstudie und Vergleich mit bisherigen Studienergebnissen. *Blackwell, Berlin* 2000:23-29
74. Rausch M, Scheffler K, Rudin M, Radue EW. Analysis of input functions from different arterial branches with gamma variate functions and cluster analysis for quantitative blood volume measurements. *Magn Reson Imaging* 2000;18:1235-43
75. Seifritz E, Bilecen D, Haenggi D, Haselhorst R, Radue EW, Wetzel S, Seelig J, Scheffler K. Effect of ethanol on BOLD response to acoustic stimulation: implications for neuropharmacological fMRI. *Psychiat Res* 2000;99:1-13

76. Stock KW, Wetzel SG, Lyrer PA, Radue EW. Quantification of blood flow in the middle cerebral artery with phase-contrast MR imaging. *Eur Radiol* 2000;10:1795-800
77. Welte D, Kappos L, Gerig G, Radue EW, Szekely G. Using spatio-temporal models to improve the segmentation of active multiple sclerosis lesions in serial MRI data and to get a better understanding of the pathophysiological processes. *Rev Neurol-France* 2000;156:105
78. Wetzel SG, Bilecen D, Lyrer P, Bongartz G, Seifritz E, Radue EW, Scheffler K. Cerebral dural arteriovenous fistulas: detection by dynamic MR projection angiography. *Am J Roentgenol* 2000;174:1293-5
79. Baumhackl U, Mertin J, Kappos L, Radue EW, Freitag P, Guseo A, Daumer M, Stauder G, for the ESEMS Study Group. The European Study on Enzyme Therapy in Multiple Sclerosis (ESEMS) - final report. *J Neurol* 2001;248:1164
80. Freitag P, De Battista E, Hardmeier M, Kooijmans M, Kappos L, Radue EW, for the-rIFN-beta-1a-in-relapsing-MS-dose-comparison-trial-study-group. Counting new and enlarging T2 lesions: what is the best Counting new and enlarging T2 lesions: what is the best interval? *Mult Scler* 2001;7:88
81. Freitag P, Greenlee MW, Wachter K, Ettlin TM, Radue EW. fMRI response during visual motion stimulation in patients with late whiplash syndrome. *Neurorehabil Neural Repair* 2001;15:31-7
82. Freitag P, Hardmeier M, Fisher E, Rudick RA, Kooijmans M, Clanet M, Kappos L, Radue EW. Time course of annual brain atrophy rates in the dose comparison-study of rIFN beta-1a (Avonex) in relapsing multiple sclerosis. *Mult Scler* 2001;7:42
83. Freitag P, Mueller B, Radue EW, Kapos L, for the-MS-MRI-evaluation-centre-Basel, Switzerland. Individual changes of chronic black holes. *Mult Scler* 2001;7:41
84. Hardmeier M, Freitag P, Fisher E, Rudick RA, Kooijmans M, Clanet M, Radue EW, Kappos L. Brain parenchymal fraction (BPF) detects whole brain volume changes within months in MS. *Mult Scler* 2001;7:43
85. Hausmann E, Radue E, Mindermann TH, Gratzl O. Coagulopathy induced spinal intradural extramedullary haematoma: report of three cases and review of the literature. *Acta Neurochir* 2001;143:135-40
86. Kristoferitsch W, Seeldrayers P, Kyriallis K, Brochet B, Confavreux C, Clanet M, Cesaro P, Defer G, Edan G, Lyon-Caen O, Pelletier J, Rumbach L, Rouillet E, Vermersch P, Dengler R, Zschenderlein R, Storch-Hagenlocher B, Sailer M, Hohlfeld R, Kunze KP, Heesen C, Bamborschke P, Grunwald F, Hartung HP, Rieckmann P, DeKeyser J, Montalban X, Fernandez U, Arbizu T, Sandberg M, Kappos L, Bates D, Campbell MJ, Capildeo R, Compston A, McLellan DL, Wroe S, Young C, Clanet M, Hartung HP, Hohlfeld R, Kappos L, Radue EW, Rieckmann P, Sandberg M, Polman C, Kesselring J, Thompson A, Wekerle H, Whitehead J, Bains H, Butler E, Kooijmans-Coutinho M, McAllister A, Simonian N, White K, Anderson D, Liddiard S, Keane R. Double-blind randomized multicenter dose-comparison study of interferon-beta-1a (AVONEX): rationale, design and baseline data. *Mult Scler* 2001;7:179-183
87. Leppert D, Radue EW. Medial medullary syndrome due to vertebral artery dissection. *J Neurol Neurosur Ps* 2001;70:130-1
88. Penner IK, Rausch M, Kappos L, Radue EW. Does altered functional activation in MS patients reflect loss or presence of compensatory brain mechanisms? *Mult Scler* 2001;7:13
89. Penner IK, Rausch M, Hardmeier M, Kappos L, Radue EW. Altered functional activation in MS patients with reduced attentional performance demonstrated with functional MRI. *Neuroimage* 2001;13:5347
90. Radue EW, Kappos L, Simonian N, Kooijmans M, Clanet M, Slasor P, Rudick RA. MRI results of the European Interferon beta-1a (Avonex) dose-comparison study. *Mult Scler* 2001;7:93
91. Rausch M, Sauter A, Fröhlich J, Neubacher U, Radue EW, Rudin M. Dynamic patterns of USPIO enhancement can be observed in macrophages after ischemic brain damage. *Magnet Reson Med* 2001;46:1018-22
92. Seifritz E, Di Salle F, Bilecen D, Radue EW, Scheffler K. Auditory system: functional magnetic resonance imaging. *Neuroimag Clin N Am* 2001;11:275-96

93. Welti D, Gerig G, Radue EW, Kappos L, Szekely G. Spatio-temporal Segmentation of Active Multiple Sclerosis. *Lecture Notes in Computer Science* 2001;2082:438
94. Wetzel SG, Haselhorst R, Bilecen D, Lyrer PA, Seifritz E, Bongartz G, Radue EW, Scheffler K. Preliminary experience with dynamic MR projection angiography in the evaluation of cervicocranial steno-occlusive disease. *Eur Radiol* 2001;11:295-302
95. Freitag P, Kappos L, Baumhackl U, Daumer M, Freitag P, Kappos L, Guseo A, Mertin J, Stauder G, Radue EW. Magnetic resonance imaging results of a randomised double-blind placebo-controlled treatment trial of hydrolytic enzymes in relapsing multiple sclerosis. *J Neurol* 2001;248:1161
96. Batukan C, Holzgreve W, Bubl R, Visca E, Radue EW, Tercanli S. Prenatal diagnosis of an infratentorial subdural hemorrhage: case report. *Ultrasound Obst Gyn* 2002;19:407-9
97. Bilecen D, Radu EW, Schulte AC, Hennig J, Scheffler K, Seifritz E. fMRI of the auditory cortex in patients with unilateral carotid artery steno-occlusive disease. *J Magn Reson Imaging* 2002;15:621-627
98. Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, Kooijmans-Coutinho MF, Tsao EC, Sandrock AW, and the-European-IFN-beta-1a-(Avonex)-Dose-Comparison-Study-Investigators. A randomized, double-blind, dose-comparison study of interferon beta-1a (Avonex) in relapsing multiple sclerosis. *Neurology* 2002;59:1507-1517
99. Czaplinski A, Freitag P, Radue EW, Kappos L. The natural course of multiple sclerosis: predictive value of lesion volume in T2-weighted brain MRI. *J Neurol* 2002;249:1/82
100. Hardmeier M, Freitag P, Wagenpfeil S, Fisher E, Rudick RA, Kooijmans M, Clanet M, Radue EW, Kappos L. Detectable atrophy occurs within three months in relapsing-remitting MS (RRMS). *Neurology* 2002;58:p67.002
101. Hardmeier M, Freitag P, Wagenpfeil S, Fisher E, Rudick RA, Kooijmans M, Clanet M, Radue EW, Kappos L. Short and long term brain volume changes after initiation of treatment with rIFN-beta-1a in multiple sclerosis. *J Neurol* 2002;249:46
102. Penner IK, Kappos L, Rausch M, Opwis K, Radue EW. Does functional MRI allow inferences about cognitive training efficacy in multiple sclerosis? *Mult Scler* 2002;8:39
103. Radue EW, Kappos L, Simonian N, Kooijmans M, Clanet M, Slasor P, Rudick RA, and the-European-Interferon-beta-1a-Dose-Comparison-Study-Group. MRI results of the European Interferon beta-1a dose comparison study. *Neurology* 2002;58:A204
104. Roelcke U, Hausmann O, Merlo A, Missimer J, Maguire RP, Freitag P, Radue EW, Weinreich R, Gratzl O, Leenders KL. PET imaging drug distribution after intratumoral injection: the case for (124)I-iododeoxyuridine in malignant gliomas. *J Nucl Med* 2002;43:1444-51
105. Wiesner W, Wetzel SG, Kappos L, Hoshi MM, Witte U, Radue EW, Steinbrich W. Swallowing abnormalities in multiple sclerosis: correlation between videofluoroscopy and subjective symptoms. *Eur Radiol* 2002;12:789-92
106. Ziswiler M, Radue EW, Romero J. Chondrocalcinosis in an isolated suprapatellar pouch with recurrent effusion. *Arthroscopy* 2002;18:E14
107. Berneis K, Buitrago-Tellez C, Muller B, Keller U, Tsakiris DA. Antiphospholipid syndrome and endocrine damage: why bilateral adrenal thrombosis? *Eur J Haematol* 2002;71:299-302.
108. De Vera A, Bacelar O, Brueck W, Panzara M, Kappos L, Radue EW. Comparison of multiple sclerosis patients with different enhancement patterns. A cross-sectional MRI study. *Mult Scler* 2003;9:111
109. Hardmeier M, Wagenpfeil S, Fisher E, Rudick RA, Kooijmans M, Clanet M, Radue EW, Kappos L. Predictors of atrophy during treatment with rIFN beta-1a i.m. in relapsing multiple sclerosis: a three year follow-up. *Neurology* 2003;60:A301
110. Hardmeier M, Wagenpfeil S, Freitag P, Fisher E, Rudick RA, Kooijmans M, Clanet M, Radue EW, Kappos L, for the-European-Interferon-beta-1a-in-Relapsing-MS-Dose-Comparison-Trial-Study-Group. Atrophy is detectable within a 3-month period in untreated patients with active relapsing-remitting multiple sclerosis. *Arch Neurol* 2003;60:1736-1739

111. Meckel S, Buitrago-Tellez C, Herrmann R, Jacob AL. Stenting for pulmonary artery stenosis due to a recurrent primary leiomyosarcoma. *J Endovas Ther* 2003;10:141-6.
112. Penner IK, De Vera A, Radue EW, Opwis K, Kappos L. Cognitive decline in MS: How does behaviour, structure and function fit together? *Mult Scler* 2003;9:9
113. Penner IK, Rausch M, Kappos L, Opwis K, Radue EW. Analysis of impairment related functional architecture in MS patients during performance of different attention tasks. *J Neurol* 2003;250:461-72
114. Radue EW, Kappos L. Vancouver consortium of MS center's magnetic resonance imaging guidelines. *The International MS Journal* 2003;10:131-133
115. Seifritz E, Esposito F, Neuhoﬀ JG, Luthi A, Mustovic H, Dammann G, von Bardeleben U, Radue EW, Cirillo S, Tedeschi G, Di Salle F. Differential sex-independent amygdala response to infant crying and laughing in parents versus nonparents. *Biol Psychiat* 2003;54:1367-1675
116. Weber JF, Kirsch E, Radue EW, Steck AJ, Kaiser HJ, Lyrer PA. Angioplasty in a patient with ocular ischemia due to occlusion of the internal and stenosis of the external carotid artery. *Cerebrovasc Dis* 2003;16:436-9.
117. Weder C, Baltariu GM, Wyler KA, Gober HJ, Lienert C, Schluep M, Radue EW, De Libero G, Kappos L, Duda P. Glatiramer acetate specific T-cell reactivity correlates with clinical and MRI response to therapy. *Neurology* 2003;60:A395
118. Bakshi R, Hutton GJ, Miller JR, Radue EW. The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis. *Neurology* 2004;63:3-11
119. Bakshi R, Hutton GJ, Miller JR, Radue EW. The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis. *Neurology* 2004;63:3-11
120. De Vera A, Bacelar O, Schoetzau A, Hardmeier M, Gass A, Kappos L, Radue EW. Prediction of treatment response to interferon beta-1a based on MRI analysis at month 6. *Mult Scler* 2004;10:228
121. Engelter ST, Wetzel SG, Radue EW, Rausch M, Steck AJ, Lyrer PA. The clinical significance of diffusion-weighted MR imaging in infratentorial strokes. *Neurology* 2004;62:574-80
122. Gross T, Jacob AL, Messmer P, Regazzoni P, Steinbrich W, Huegli RW. Transverse acetabular fracture: hybrid minimal access and percutaneous CT-navigated fixation. *Am J Roentgenol* 2004;183:1000-2.
123. Gschwandtner U, Borgwardt S, Aston J, Drewe M, Radue EW, Riecher-Rössler A. [Chronic subdural hemorrhage in a patient with suspected schizophrenia prodrome]. *Nervenarzt* 2004;75:691-3
124. Kappos L, Achtnichts L, Durelli L, Fernandez O, Petereit H, De Sa J, Siva A, Radue EW, Daumer M, for the-BEST-PGx-Study-Group. BEST-PGx: design of a pharmacogenomic and pharmacogenetic study to identify criteria for prediction of treatment response to interferon beta-1b. *Mult Scler* 2004;10:246
125. Kappos L, Kuhle J, Gass A, Achtnichts L, Radue EW. Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future? *J Neurol* 2004;251:57-64
126. Ledermann HP, Heinz W, Stuckmann G, Steinbrich W. Hat die transabdominelle Sonographie einen Stellenwert in der radiologischen Abklärung des Magen-Darm-Traktes? *Schweiz Rundsch Med Prax* 2004
127. Penner IK, Hardmeier M, Vogt A, Stoecklin M, Raselli C, Opwis K, Radue EW, Kappos L. Experimental induced fatigue in MS patients. *Mult Scler* 2004;10:126
128. Saborowski O, Schindler T, Bremerich J. Intramurales Hämatom der Aorta mit Progression in eine Stanford-A-Dissektion. *Rofo-Fortschr Rontgenstrahl* 2004;176:758-770
129. Baumhackl U, Kappos L, Radue EW, Freitag P, Guseo A, Daumer M, Mertin J. A randomized, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis. *Mult Scler* 2005;11:166-8
130. Calabresi P, Stuart W, Confavreux C, Galetta S, Radue EW, Rudick R, Lublin F, Weinstock-Guttman B, Wynn D, Lynn F, Panzara M, Sandrock A, for the SENTINEL Investigators. The

- incidence and clinical impact of anti-natalizumab antibodies from a phase III trial of multiple sclerosis (SENTINEL). *J Neurol* 2005;252:II/128
131. Haller S, Bartsch AJ, Radue EW, Klarhöfer M, Seifritz E, Scheffler K. Effect of fMRI acoustic noise on non-auditory working memory task: comparison between continuous and pulsed sound emitting EPI. *Magn Reson Mater Phys* 2005;18:263-71
 132. Haller S, Radue EW. What is different about a radiologist's brain? *Radiology* 2005;236:983-9
 133. Haller S, Radue EW, Erb M, Grodd W, Kircher T. Overt sentence production in event-related fMRI. *Neuropsychologia* 2005;43:807-14
 134. Hardmeier M, Radue EW, Kappos L. Re: Short-term brain atrophy changes in relapsing-remitting multiple sclerosis. *J Neurol Sci* 2005;231:101; author reply 103-4
 135. Hardmeier M, Wagenpfeil S, Freitag P, Fisher E, Rudick RA, Kooijmans M, Clanet M, Radue EW, Kappos L, European-IFN-1a-in-Relapsing-MS-Dose-Comparison-Trial-Study-Group. Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. *Neurology* 2005;64:236-40
 136. Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S, European-Interferon-Beta-1a-IM-Dose-Comparison-Study-Investigators. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. *Neurology* 2005;65:40-7
 137. Kappos L, Radue EW, Antel J, Comi G, Montalban X, O'Connor P, Bettoni-Ristic O, Haas T, Preiss R, Korn A, on behalf of the FTY720D2201 Study Group. FTY720 in relapsing MS: results of a double-blind placebo-controlled trial with a novel oral immunomodulator. *J Neurol* 2005;252:II/41
 138. Kappos L, Radue EW, Antel J, Comi G, Montalban X, O'Connor P, Polam C, Bettoni-Ristic O, Haas T, Preiss R, Korn A, for the FTY720D2201 Study Group. Promising results with a novel oral immunomodulator - FTY720 - in relapsing multiple sclerosis. *Mult Scler* 2005;11:13
 139. Kuhle J, Lindberg RL, Hoffmann F, Wu S, Radue EW, Kappos L. Antimyelin antibodies in clinically isolated syndromes correlate with inflammation and conversion to multiple sclerosis. *Mult Scler* 2005;11:153
 140. Meckel S, Lovblad KO, Abdo G, Ruiz DS, Delavelle J, Radue EW, Ruefenacht DA, Wetzel SG. Arterialization of cerebral veins on dynamic MDCT angiography: a possible sign of a dural arteriovenous fistula. *Am J Roentgenol* 2005;184:1313-6
 141. O'Connor P, Antel J, Comi G, Montalban X, Radue EW, Haas T, De Vera A, Karlsson G, Kappos L. Phase II study with oral FTY720 in relapsing MS: results of the dose-blinded active drug extension phase at 12 months. *Mult Scler* 2005;11:182
 142. Radue EW, Stuart W, Calabresi P, Confavreux C, Galetta S, Rudick R, Lublin F, Weinstock-Guttman B, Wynn D, Lynn F, Panzara M, Sandrock A, for the SENTINEL Investigators. Magnetic resonance imaging results from SENTINEL: a randomized controlled trial of natalizumab and interferon beta-1a in multiple sclerosis. *J Neurol* 2005;252:II/149
 143. Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, for the SENTINEL Investigators. SENTINEL: a randomised controlled trial of natalizumab (Tysabri) and interferon beta-1a (Avonex) in relapsing multiple sclerosis. Magnetic resonance imaging results. *J Neurol Sci* 2005;236:72
 144. Sollberger M, Lyrer P, Baumann T, Radue EW, Steck AJ, Wetzel SG. Isolated bilateral abducent nerve palsy due to a spontaneous left-side dural carotid cavernous fistula Type Barrow C. *J Neurol* 2005;252:372-3
 145. Stuart W, Calabresi P, Confavreux C, Galetta S, Radue EW, Rudick R, Lublin F, Weinstock-Guttman B, Wynn D, Lynn F, Panzara M, Sandrock A, for the SENTINEL Investigators. The efficacy of natalizumab add-on therapy in patients with relapsing multiple sclerosis: subgroup analysis of SENTINEL. *J Neurol* 2005;252:II/149
 146. Taschner CA, Kirsch EC, Scheffler K, Wetzel SG, Schulte-Moenting J, Kappos L, Radue EW. Optimizing brain MRI protocols in the follow-up of patients with multiple sclerosis T2-weighted

- MRI of the brain after the administration of gadopentetate dimeglumine. *Magn Reson Imaging* 2005;23:469-74
147. Taschner CA, Wetzel SG, Tolnay M, Froehlich J, Merlo A, Radue EW. Characteristics of ultrasmall superparamagnetic iron oxides in patients with brain tumors. *Am J Roentgenol* 2005;185:1477-86
 148. Weder C, Baltariu GM, Wyler KA, Gober HJ, Lienert C, Schlupe M, Radue EW, Libero G, Kappos L, Duda PW. Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis. *Eur J Neurol* 2005;12):869-78
 149. Wetzel SG, Martin JB, Radue EW, Rüfenacht DA. [Percutaneous vertebroplasty: a minimal-invasive procedure for pain treatment]. *Schweiz Rundsch Med Prax* 2005;94:595-8
 150. Ammann M, Hirsch J, Achtnichts L, Kappos L, Radue EW, Gass A. A functional connectivity study in multiple sclerosis patients comparing 2 principles of data sampling. *Mult Scler* 2006;12:41
 151. Bonati LH, Kessel-Schaefer A, Linka AZ, Buser P, Wetzel SG, Radue EW, Lyrer PA, Engelter ST. Diffusion-weighted imaging in stroke attributable to patent foramen ovale: significance of concomitant atrial septum aneurysm. *Stroke* 2006;37:2030-4
 152. Borgwardt SJ, Radue EW, Götz K, Aston J, Drewe M, Gschwandtner U, Haller S, Pflüger M, Stieglitz RD, McGuire PK, Riecher-Rössler A. Radiological findings in individuals at high risk of psychosis. *J Neurol Neurosurg Ps* 2006;77:229-33
 153. Borgwardt SJ, Riecher-Rössler A, Dazzan P, Chitnis X, Aston J, Drewe M, Gschwandtner U, Haller S, Pflüger M, Rechsteiner E, D'Souza M, Stieglitz RD, Radue EW, McGuire PK. Regional Gray Matter Volume Abnormalities in the At Risk Mental State. *Biol Psych* 2006
 154. Haller S, Wetzel SG, Radue EW, Bilecen D. Mapping continuous neuronal activation without an ON-OFF paradigm: initial results of BOLD ceiling fMRI. *Eur J Neurosci* 2006;24:2672-8
 155. Kappos L, Achtnichts L, Radue EW, Wu S, for the BEST PGx Study Group. BEST PGx: Baseline data of a pharmacogenomic and pharmacogenetic study to identify predictors of treatment response to interferon-beta-1. *Mult Scler* 2006;12:198
 156. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW, FTY720 D2201 Study Group. Oral fingolimod (FTY720) for relapsing multiple sclerosis. *N Engl J Med* 2006;355:1124-40
 157. Kappos L, Antel JP, Comi G, Montalban X, Radue EW, De Vera A, Pohlman C, O'Connor P, on behalf of the FTY720D2201 Study Group. Oral fingolimod (FTY720) in relapsing multiple sclerosis: 24-month results of the phase II study. *Mult Scler* 2006;12:101
 158. Meckel S, Mекle R, Taschner C, Haller S, Scheffler K, Radue EW, Wetzel SG. Time-resolved 3D contrast-enhanced MRA with GRAPPA on a 1.5-T system for imaging of craniocervical vascular disease: initial experience. *Neuroradiology* 2006;48:291-9
 159. Penner IK, Kappos L, Rausch M, Opwis K, Radue EW. Therapy-induced plasticity of cognitive functions in MS patients: insights from fMRI. *J Physiol-Paris* 2006;99:455-62
 160. Radue EW, O'Connor P, Antel J, Comi G, Montalban X, De Vera A, Tang D, Kappos L, on behalf of the FTY720D2201 Study Group. Oral fingolimod (FTY720) in relapsing multiple sclerosis: MRI results of a placebo-controlled phase II study and active drug extension. *Mult Scler* 2006;12:101
 161. Rudick RA, Miller DM, Hutchinson M, O'Connor PW, Havrdova E, Kappos L, Miller DH, Phillips JT, Polman CH, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Giovannoni G, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, for the AFFIRM and SENTINEL Investigators. The relationship between disease severity and health-related quality of life in patients with relapsing-remitting multiple sclerosis. *Mult Scler* 2006;12:18
 162. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lubin F, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara M, Sandrock AW, for the SENTINEL Investigators. A randomized placebo-controlled trial of natalizumab in combination with interferon beta-1a for relapsing multiple sclerosis. *New Eng J Med* 2006;354:911-923

163. Simon JH, Li D, Traboulsee A, Coyle PK, Arnold DL, Barkhof F, Frank JA, Grossman R, Paty DW, Radue EW, Wolinsky JS. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. *Am J Neuroradiol* 2006;27:455-61
164. VOGT A, KAPPOS L, OPWIS K, RADUE EW, PENNER IK. Computer-based working memory training in patients with multiple sclerosis - Design of a randomised study. *Mult Scler* 2006;12:142
165. Weier K, Naegelin Y, Thoeni A, Hirsch JG, Kappos L, Leppert D, Radue EW, Gass A. Biplanar whole-cord magnetic resonance imaging using parallel imaging in multiple sclerosis. *J Neurol* 2006;253:11/27
166. Weier K, Naegelin Y, Thoeni A, Hirsch JG, Kappos L, Leppert D, Radue EW, Gass A. Biplanar whole-cord magnetic resonance imaging using parallel imaging in multiple sclerosis: a 1-year follow-up study. *Mult Scler* 2006; 12:173
167. Yousry TA, Major EO, Ryschewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jäger HR, Clifford DB. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. *N Engl J Med* 2006;354:924-33
168. Balcer LJ, Galetta SL, Calabresi PA, Confavreux C, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. *Neurology* 2007;68:1299-304
169. Barkhof F, Polman CH, Radue EW, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, Montalbán X, Poppe P, de Vos M, Lasri F, Bauer L, Dahms S, Wagner K, Pohl C, Sandbrink R. Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. *Arch Neurol* 2007;64:1292-8
170. Borgwardt SJ, McGuire PK, Aston J, Berger G, Dazzan P, Gschwandtner U, Pflüger M, D'Souza M, Radue EW, Riecher-Rössler A. Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. *Br J Psychiatry Suppl* 2007;51:69-75
171. Borgwardt SJ, Radue EW, Riecher-Rössler A. Cavum septum pellucidum in patients with first episode psychosis and individuals at high risk of psychosis. *Eur Psychiat* 2007;22:264
172. Borgwardt SJ, Riecher-Rössler A, Dazzan P, Chitnis X, Aston J, Drewe M, Gschwandtner U, Haller S, Pflüger M, Rechsteiner E, D'Souza M, Stieglitz RD, Radue EW, McGuire PK. Regional gray matter volume abnormalities in the at risk mental state. *Biol Psychiatry* 2007;61:1148-56
173. Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, Kappos L, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Lublin FD, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, AFFIRM and SENTINEL Investigators. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. *Neurol* 2007;69:1391-403
174. Haller S, Klarhoefer M, Schwarzbach J, Radue EW, Indefrey P. Spatial and temporal analysis of fMRI data on word and sentence reading. *Eur J Neurosci* 2007;26:2074-84
175. Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH, Ravnborg M, Hauser SL, Rudick RA, Weiner HL, O'Connor PW, King J, Radue EW, Yousry T, Major EO, Clifford DB. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. *Lancet Neurol* 2007;6:431-41
176. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radue EW, Bauer L, Dahms S, Lanius V, Pohl C, Sandbrink R, BENEFIT Study Group. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. *Lancet* 2007;370:389-97
177. Kuhle J, Lindberg RL, Regeniter A, Mehling M, Hoffmann F, Reindl M, Berger T, Radue EW, Leppert D, Kappos L. Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. *J Neurol* 2007;254:160-8

178. Meckel S, Maier M, Ruiz DS, Yilmaz H, Scheffler K, Radue EW, Wetzel SG. MR angiography of dural arteriovenous fistulas: diagnosis and follow-up after treatment using a time-resolved 3D contrast-enhanced technique. *Am J Neuroradiol* 2007;28:877-84
179. Riecher-Rössler A, Gschwandtner U, Aston J, Borgwardt S, Drewe M, Fuhr P, Pflüger M, Radue W, Schindler CH, Stieglitz RD. The Basel early-detection-of-psychosis (FEPSY)-study-design and preliminary results. *Acta Psychiatr Scand* 2007;115:114-25
180. Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, AFFIRM and SENTINEL Investigators. Health-related quality of life in multiple sclerosis: effects of natalizumab. *Ann Neurol* 2007;62:335-46
181. Wetzel S, Meckel S, Frydrychowicz A, Bonati L, Radue EW, Scheffler K, Hennig J, Markl M. In vivo assessment and visualization of intracranial arterial hemodynamics with flow-sensitized 4D MR imaging at 3T. *Am J Neuroradiol* 2007;28:433-8
182. Borgwardt SJ, Fusar-Poli P, Radue EW, Riecher-Rössler A. Insular pathology in the at-risk mental state. *Eur Arch Psychiatry Clin Neurosci* 2008;258: 254-255
183. Borgwardt SJ, McGuire P, Fusar-Poli P, Radue EW, Riecher-Rössler A. Anterior cingulate pathology in the prodromal stage of schizophrenia. *Neuroimage* 2008;39(2): 553-4
184. Garren H, Robinson WH, Krasulova E, Havrdova E, Nadj C, Selmaj K, Losy J, Nadj I, Radue EW, Kidd BA, Gianettoni J, Tersini K, Utz PJ, Valone F, Steinman L. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. *Ann Neurol* 2008, 63: 611-620
185. Haller S, Fasler D, Ohlendorf S, Radue EW, Greenlee MW. Neural activation associated with corrective saccades during tasks with fixation, pursuit and saccades. *Exp Brain Res* 2008;184(1): 83-94
186. Meckel S, Glücker TM, Kretschmar M, Scheffler K, Radue EW, Wetzel SG. Display of dural sinuses with time-resolved, contrast-enhanced three-dimensional MR venography. *Cerebrovasc Dis* 2008;25(3): 217-24
187. Borgwardt SJ, McGuire PK, Aston J, Gschwandtner U, Pflüger MO, Stieglitz RD, Radue EW, Riecher-Rössler A. Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. *Schizophr Res* 2008;106(2-3):108-14
188. Borgwardt SJ, Fusar-Poli P, Radue EW, Riecher-Rössler A. Insular pathology in the at-risk mental state. *Eur Arch Psychiatry Clin Neurosci* 2008;258(4):254-5
189. Borgwardt SJ, McGuire P, Fusar-Poli P, Radue EW, Riecher-Rössler A. Anterior cingulate pathology in the prodromal stage of schizophrenia. *Neuroimage* 2008;39(2):553-4
190. Haller S, Fasler D, Ohlendorf S, Radue EW, Greenlee MW. Neural activation associated with corrective saccades during tasks with fixation, pursuit and saccades. *Exp Brain Res* 2008;184:83-94
191. Weier K, Naegelin Y, Thoeni A, Hirsch JG, Kappos L, Steinbrich W, Radue EW, Gass A. Non-communicating syringomyelia: a feature of spinal cord involvement in multiple sclerosis. *Brain* 2008;131:1776-82
192. Sailer M, Fazekas F, Gass A, Kappos L, Radue EW, Rieckmann P, Toyka K, Wiendl H, Bendszus M. Cerebral and spinal MRI examination in patients with clinically isolated syndrome and definite multiple sclerosis. *Rofo* 2008;180:994-1001
193. Bendfeldt K, Kappos L, Radue EW, Borgwardt SJ. Progression of gray matter atrophy and its association with white matter lesions in relapsing-remitting multiple sclerosis. *J Neurol Sci* 2009;285:268-9
194. Bendfeldt K, Kuster P, Traud S, Egger H, Winklhofer S, Mueller-Lenke N, Naegelin Y, Gass A, Kappos L, Matthews PM, Nichols TE, Radue EW, Borgwardt SJ. Association of regional gray matter volume loss and progression of white matter lesions in multiple sclerosis - A longitudinal voxel-based morphometry study. *Neuroimage* 2009;45:60-7
195. Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, Barkhof F, Radue EW, Lindberg RL, Uitdehaag BM, Johnson MR, Angelakopoulou A, Hall L, Richardson JC, Prinjha RK, Gass A, Geurts JJ, Kragt J, Sombekke M, Vrenken H, Qualley P, Lincoln RR, Gomez R, Caillier SJ,

- George MF, Mousavi H, Guerrero R, Okuda DT, Cree BA, Green AJ, Waubant E, Goodin DS, Pelletier D, Matthews PM, Hauser SL, Kappos L, Polman CH, Oksenberg JR. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. *Hum Mol Genet* 2009;18:767-78
196. Palmowski-Wolfe AM, Kober C, Berg I, Kunz C, Wetzel S, Buitrago-Télez C, Radue EW, Scheffler K. Globe restriction in a severely myopic patient visualized through oculodynamic magnetic resonance imaging (od-MRI). *J Aapos* 2009;13322-4
 197. Smieskova R, Fusar-Poli P, Allen P, Bendfeldt K, Stieglitz RD, Drewe J, Radue EW, McGuire PK, Riecher-Rössler A, Borgwardt SJ. The effects of antipsychotics on the brain: what have we learnt from structural imaging of schizophrenia?- a systematic review. *Curr Pharm Des* 2009;15:2535-49
 198. Haller S, Borgwardt SJ, Schindler C, Aston J, Radue EW, Riecher-Rössler A. Can cortical thickness asymmetry analysis contribute to detection of at-risk mental state and first-episode psychosis? A pilot study. *Radiology* 2009;250:212-21
 199. Bloch C, Kaiser A, Kuenzli E, Zappatore D, Haller S, Franceschini R, Luedi G, Radue EW, Nitsch C. The age of second language acquisition determines the variability in activation elicited by narration in three languages in Broca's and Wernicke's area. *Neuropsychologia* 2009;47:625-33
 200. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radue EW, Metz C, Bauer L, Lanius V, Sandbrink R, Pohl C, BENEFIT Study Group. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. *Lancet Neurol* 2009;8:987-97
 201. Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, AFFIRM and SENTINEL Investigators. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. *J Neurol* 2009;256:405-15
 202. O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann CH, Kappos L, FTY720 D2201 Study Group. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. *Neurology* 2009;72:73-9
 203. Rudick RA, Pace A, Rani MR, Hyde R, Panzara M, Appachi S, Shrock J, Maurer SL, Calabresi PA, Confavreux C, Galetta SL, Lublin FD, Radue EW, Ransohoff RM. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. *Neurology* 2009;72:1989-93
 204. Stüve O, Cravens PD, Frohman EM, Phillips JT, Remington GM, von Geldern G, Cepok S, Singh MP, Tervaert JW, De Baets M, MacManus D, Miller DH, Radue EW, Cameron EM, Monson NL, Zhang S, Kim R, Hemmer B, Racke MK. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. *Neurology* 2009;72:396-401
 205. Comi G, O'Connor P, Montalban X, Antel J, Radue EW, Karlsson G, Pohlmann H, Aradhye S, Kappos L, FTY720D2201 Study Group. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. *Mult Scler* 2010;16:197-207
 206. Buehlmann E, Berger GE, Aston J, Gschwandtner U, Pflueger MO, Borgwardt SJ, Radue EW, Riecher-Rössler A. Hippocampus abnormalities in at risk mental states for psychosis? A cross-sectional high resolution region of interest magnetic resonance imaging study. *J Psychiatr Res* 2010;44:447-53
 207. Sahraian MA, Radue EW, Haller S, Kappos L. Black holes in multiple sclerosis: definition, evolution, and clinical correlations. *Acta Neurol Scand* 2010;122:1-8
 208. Borgwardt S, Smieskova R, Bendfeldt K, Bühlmann E, Berger G, Aston J, Gschwandtner U, Pflueger M, Stieglitz RD, Riecher-Rössler A, Radue EW. Hippocampal volume reduction specific for later transition to psychosis or substance-associated effects? *J Psychiatry Neurosci* 2010;35:214-5
 209. Palmowski-Wolfe AM, Berg I, Wetzel S, Kunz C, Radue EW, Scheffler K, Buitrago-Tellez C, Kober C. Bilateral VI nerve injury. *Ophthalmology* 2010;117:398

210. Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. *J Neurol Sci* 2010;292:28-35
211. Bendfeldt K, Egger H, Nichols TE, Loetscher P, Denier N, Kuster P, Traud S, Mueller-Lenke N, Naegelin Y, Gass A, Kappos L, Radue EW, Borgwardt SJ. Effect of immunomodulatory medication on regional gray matter loss in relapsing-remitting multiple sclerosis - a longitudinal MRI study. *Brain Res* 2010;1325:174-82
212. Bendfeldt K, Blumhagen JO, Egger H, Loetscher P, Denier N, Kuster P, Traud S, Mueller-Lenke N, Naegelin Y, Gass A, Hirsch J, Kappos L, Nichols TE, Radue EW, Borgwardt SJ. Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reduction in relapsing-remitting multiple sclerosis. *Hum Brain Mapp* 2010;10:1542-55
213. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. *N Engl J Med* 2010;362:387-401
214. Garcia M, Gloor M, Wetzel SG, Radue EW, Scheffler K, Bieri O. Characterization of normal appearing brain structures using high-resolution quantitative magnetization transfer steady-state free precessing imaging. *Neuroimage* 2010; 52:532-7
215. Bendfeldt K, Kappos L, Radue EW, Borgwardt S. Longitudinal spatiotemporal distribution of gray and white matter pathology in multiple sclerosis. *AJNR Am J Neuroradiol* 2010;31:E45
216. Smieskova R, Fusar-Poli P, Allen P, Bendfeldt K, Stieglitz RD, Drewe J, Radue EW, McGuire PK, Riecher-Rössler A, Borgwardt SJ. Neuroimaging predictors of transition to psychosis - a systematic review and meta-analysis. *Neurosci Biobehav Rev* 2010;34:1207-22
217. Sahraian MA, Radue EW, Haller S, Kappos L. Black holes in multiple sclerosis: definition, evolution, and clinical correlations. *Acta Neurol Scand* 2010;122:1-8
218. Sombekke MH, Jafari N, Bendfeldt K, Mueller-Lenke N, Radue EW, Naegelin Y, Kappos L, Matthews PM, Polman CH, Barkhof F, Hintzen R, Geurts JJ. No influence of KIF1B on neurodegenerative markers in multiple sclerosis. *Neurology* 2011;76:1843-5
219. Roosendaal SD, Bendfeldt K, Vrenken H, Polman CH, Borgwardt S, Radue EW, Kappos L, Pelletier D, Hauser SL, Matthews PM, Barkhof F, Geurts JJ. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. *Mult Scler* 2011;17:1098-106
220. Garcia M, Gloor M, Bieri O, Wetzel SG, Radue EW, Scheffler K. MTR variations in normal adult brain structures using balanced steady-state free progression. *Neuroradiology* 2011;53:159-67
221. Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, Hartung HP, Havrdová E, Hillert J, Hohlfeld R, Kremenchutzky M, Lyon-Caen O, Miller A, Pozzilli C, Ravnborg M, Saida T, Sindic C, Vass K, Clifford DB, Hauser S, Major EO, O'Connor PW, Weiner HL, Clanet M, Gold R, Hirsch HH, Radue EW, Sørensen PS, King J. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. *Lancet Neurol* 2011;10:745-58
222. Amann M, Dössegger LS, Penner IK, Hirsch JG, Raselli C, Calabrese P, Weier K, Radue EW, Kappos L, Gass A. Altered functional adaptation to attention and working memory tasks with increasing complexity in relapsing-remitting multiple sclerosis patients. *Hum Brain Mapp* 2011;32:353-60
223. Büschlen J, Berger GE, Borgwardt SJ, Aston J, Gschwandtner U, Pflueger MO, Kuster P, Radue EW, Stieglitz RD, Riecher-Rössler A. Pituitary volume increase during emerging psychosis. *Schizophr Res.* 2011;125:41-8
224. Kuhle J, Gosert R, Bühler R, Derfuss T, Sutter R, Yaldizli O, Radue EW, Ryschkevitch C, Major EO, Kappos L, Frank S, Hirsch HH. Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. *Neurology* 2011;77:2010-6
225. Barkhof F, Simon JH, Fazekas F, Rovaris M, Kappos L, de Stefano N, Polman CH, Petkau J, Radue EW, Sormani MP, Li DK, O'Connor P, Montalban X, Miller DH, Filippi M. MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. *Nat Rev Neurol* 2011;8:13-21

226. Metz I, Radue EW, Oterino A, Kümpfel T, Wiendl H, Schippling S, Kuhle J, Sahraian MA, Gray F, Jakl V, Häusler D, Brück W. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. *Acta Neuropathol* 2012;123:235-45
227. Smieskova R, Allen P, Simon A, Aston J, Bendfeldt K, Drewe J, Gruber K, Gschwandtner U, Klarhoefer M, Lenz C, Scheffler K, Stieglitz RD, Radue EW, McGuire P, Riecher-Rössler A, Borgwardt SJ. Different duration of at-risk mental state associated with neurofunctional abnormalities. A multimodal imaging study. *Hum Brain Mapp* 2012;33:2281-94]
228. Schlaeger R, D'Souza M, Schindler C, Grize L, Dellas S, Radue E, Kappos L, Fuhr P. Prediction of long-term disability in multiple sclerosis. *Mult Scler* 2012;18:31-8
229. Berg I, Palmowski-Wolfe A, Schwenzler-Zimmerer K, Kober C, Radue EW, Zeilhofer HF, Scheffler K, Kunz C, Buitrago-Tellez C. Near-real time oculodynamic MRI: a feasibility study for evaluation of diplopia in comparison with clinical testing. *Eur Radiol* 2012;17:12-9
230. Garcia M, Gloor M, Radue EW, Stippich C, Wetzel SG, Scheffler K, Bieri O. Fast high-resolution brain imaging with balanced SSFP: interpretation of quantitative magnetization transfer towards simple MTR. *Neuroimage* 2012;59:202-11
231. Bendfeldt K, Hofstetter L, Kuster P, Traud S, Mueller-Lenke N, Naegelin Y, Kappos L, Gass A, Nichols TE, Barkhof F, Vrenken H, Roosendaal SD, Geurts JJ, Radue EW, Borgwardt SJ. Longitudinal gray matter changes in multiple sclerosis-Differential scanner and overall disease-related effects. *Hum Brain Mapp* 2012;33:1225-45
232. Weier K, Mazraeh J, Naegelin Y, Thoeni A, Hirsch JG, Fabbro T, Bruni N, Duyar H, Bendfeldt K, Radue EW, Kappos L. Biplanar MRI for the assessment of the spinal cord in multiple sclerosis. *Mult Scler* 2012;18:1560-9
233. Filli L, Hofstetter L, Kuster P, Traud S, Mueller-Lenke N, Naegelin Y, Kappos L, Gass A, Sprenger T, Nichols TE, Vrenken H, Barkhof F, Polman C, Radue EW, Borgwardt SJ, Bendfeldt K. Spatiotemporal distribution of white matter lesions in relapsing-remitting and secondary progressive multiple sclerosis. *Mult Scler* 2012;18:1577-84
234. Bendfeldt K, Klöppel S, Nichols TE, Smieskova R, Kuster P, Traud S, Mueller-Lenke N, Naegelin Y, Kappos L, Radue EW, Borgwardt SJ. Multivariate pattern classification of gray matter pathology in multiple sclerosis. *Neuroimage* 2012;60:400-8
235. Walter A, Studerus E, Smieskova R, Kuster P, Aston J, Lang UE, Radue EW, Riecher-Rössler A, Borgwardt SJ. Hippocampal volume in subjects at high risk of psychosis. A longitudinal MRI study. *Schizophr Res* 2012;142:317-22
236. Sahraian MA, Radue EW, Eshaghi A, Besliu S, Minagar A. Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis. *Eur J Neurol* 2012;19:1060-9
237. Seifert CL, Magon S, Staehle K, Zimmer C, Foerschler A, Radue EW, Pfaffenrath V, Tölle TR, Sprenger T. A case-control study on cortical thickness in episodic cluster headache. *Headache* 2012;52:1362-8
238. Tourdias T, Roggerone S, Filippi M, Kanagaki M, Rovaris M, Miller DH, Petry KG, Brochet B, Pruvo JP, Radue EW, Dousset V. Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium and superparamagnetic iron oxide-enhanced MR imaging. *Radiology* 2012;264:225-33
239. Weier K, Beck A, Magon S, Amann M, Naegelin Y, Penner IK, Thürling M, Aurich V, Derfuss T, Radue EW, Stippich C, Kappos L, Timmann D, Sprenger T. Evaluation of a new approach for semi-automatic segmentation of the cerebellum in patients with multiple sclerosis. *J Neurol* 2012;259:2673-80
240. Amann M, Achtnichts L, Hirsch JG, Naegelin Y, Gregori J, Weier K, Thoeni A, Mueller-Lenke N, Radue EW, Günther M, Kappos L, Gass A. 3D GRASE arterial spin labelling reveals an inverse correlation of cortical perfusion with the white matter lesion volume in MS. *Mult Scler* 2012;18:1570-6
241. Radue EW, O'Connor P, Polman CH, Hohlfeld R, Clabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Grancis G, Burtin P, Kappos L, for the FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis

- (FREEDOMS) Study Group. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. *Arch Neurol* 2012;Jul 2:1-11 [Epub ahead of print]
242. Strijbis EM, Inkster B, Vounou M, Naegelin Y, Kappos L, Radue EW, Matthews PM, Uitdehaag BM, Barkhof F, Polman CH, Montana G, Geurts JJ. Glutamate gene polymorphisms predict brain volumes in multiple sclerosis. *Mult Scler* 2012;Jul 31 [Epub ahead of print]
243. Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L, for the FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. *Lancet Neurol* 2012;11:420-8
244. Papadopoulou A, von Felten S, Traud S, Rahman A, Quan J, King R, Garren H, Steinman L, Cutter G, Kappos L, Radue EW. Evolution of MS lesions to black holes under DNA vaccine treatment. *J Neurol* 2012;259:1375-82
245. Yoursry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. *Ann Neurol* 2012;72:779-87
246. Weier K, Naegelin Y, Amann M, Magon S, Mueller-Lenke N, Radue EW, Kappos L, Stippich C, Gass A, Sprenger T. Six-year follow-up of a case series with non-communicating syringomyelia in multiple sclerosis. *Eur J Neurol* 2012;Dec 12 [Epub ahead of print]
247. Inkster B, Strijbis EM, Vounou M, Kappos L, Radue EW, Matthews PM, Uitdegaag BM, Barkhof F, Polman CH, Montalban G, Geurts JJ. Histone deacetylase gene variants predict brain volume changes in multiple sclerosis. *Neurobiol Aging* 2013;34:238-47
248. Sahraian MA, Radue EW, Minagar A. Neuromyelitis optica: clinical manifestation and neuroimaging features. *Neurol Clin* 2013;31:139-52

Books, book chapters

1. Roelcke U, Radue EW, Leenders KL. 11C-methionine and 82rubidium uptake in human brain tumors: comparison of carrier dependent blood-brain barrier transport. Kluwer Academic Publishers 1993;197-201
2. Radue EW, Kendall BE, Moseley IF. Computertomographie des Kopfes. Georg Thieme Verlag Stuttgart 1994
3. Freitag P, Radue E, Kappos L. Bildgebende Diagnostik bei der Multiplen Sklerose. In: Klinische Neuroimmunologie (Hg.) de Gruyter Berlin 1999;121-134
4. Gerig G, Welti D, Szekely G, Radü W, Kappos L. Quantifikation of MS lesion evolution in a serial MRI study. In: Multiple Sclerosis: Tissue destruction and repair (Hg.) Martin Dunitz, London 2001;99-111
5. Kappos L, Johnson K, Kesselring J, Radü EW. Multiple Sclerosis: Tissue destruction and repair. Martin Dunitz, London 2001
6. Penner IK, Rausch M, Kappos L, Opwis K, Radue EW. Funktionelle Bildgebung bei Multipler Sklerose. In: Bildgebung in der klinischen Neuroimmunologie (Hg.) Georg Thieme Verlag, Stuttgart 2004;57-64
7. Hardmeier M, Radue EW, Kappos L. Multiple Sklerose: Therapiemonitoring mit kranialer MRT in klinischen Studien und im klinischen Alltag. In: Bildgebung in der klinischen Neuroimmunologie (Hg.) Georg Thieme Verlag, Stuttgart 2004;91-98
8. Sahraian M.A., Radue EW. MRI Atlas of MS Lesions. Springer-Verlag Heidelberg 2008
9. Sahraian M.A., Radue EW. Neuromyelitis optica - clinical manifestations and neuroimaging features. In: Neurologic Clinics 2013;31:139-152